168 related articles for article (PubMed ID: 30184111)
1. Molecular differential diagnosis of uterine leiomyomas and leiomyosarcomas.
Mas A; Simón C
Biol Reprod; 2019 Dec; 101(6):1115-1123. PubMed ID: 30184111
[TBL] [Abstract][Full Text] [Related]
2. The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing.
Mas A; Alonso R; Garrido-Gómez T; Escorcia P; Montero B; Jiménez-Almazán J; Martín J; Pellicer N; Monleón J; Simón C
Am J Obstet Gynecol; 2019 Oct; 221(4):320.e1-320.e23. PubMed ID: 31121144
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel diagnostic gene expression signature to discriminate uterine leiomyoma from leiomyosarcoma.
Adams CL; Dimitrova I; Post MD; Gibson L; Spillman MA; Behbakht K; Bradford AP
Exp Mol Pathol; 2019 Oct; 110():104284. PubMed ID: 31301306
[TBL] [Abstract][Full Text] [Related]
4. Identification of uterine leiomyoma-specific marker genes based on DNA methylation and their clinical application.
Sato S; Maekawa R; Yamagata Y; Tamura I; Lee L; Okada M; Jozaki K; Asada H; Tamura H; Sugino N
Sci Rep; 2016 Aug; 6():30652. PubMed ID: 27498619
[TBL] [Abstract][Full Text] [Related]
5. Integrated histologic and molecular analysis of uterine leiomyosarcoma and 2 benign variants with nuclear atypia.
Gao T; Finkelman BS; Ban Y; Li Y; Yin P; Bulun SE; Lu X; Ha C; Wei JJ
Cancer Sci; 2021 May; 112(5):2046-2059. PubMed ID: 33338329
[TBL] [Abstract][Full Text] [Related]
6. Use of X-chromosome inactivation pattern to determine the clonal origins of uterine leiomyoma and leiomyosarcoma.
Zhang P; Zhang C; Hao J; Sung CJ; Quddus MR; Steinhoff MM; Lawrence WD
Hum Pathol; 2006 Oct; 37(10):1350-6. PubMed ID: 16949924
[TBL] [Abstract][Full Text] [Related]
7. Different characteristics of mitochondrial microsatellite instability between uterine leiomyomas and leiomyosarcomas.
Lee JH; Ryu TY; Cho CH; Kim DK
Pathol Oncol Res; 2011 Jun; 17(2):201-5. PubMed ID: 20853077
[TBL] [Abstract][Full Text] [Related]
8. Frequent loss of heterozygosity for chromosome 10 in uterine leiomyosarcoma in contrast to leiomyoma.
Quade BJ; Pinto AP; Howard DR; Peters WA; Crum CP
Am J Pathol; 1999 Mar; 154(3):945-50. PubMed ID: 10079273
[TBL] [Abstract][Full Text] [Related]
9. Integrative Genomic and Transcriptomic Profiling Reveals a Differential Molecular Signature in Uterine Leiomyoma versus Leiomyosarcoma.
Machado-Lopez A; Alonso R; Lago V; Jimenez-Almazan J; Garcia M; Monleon J; Lopez S; Barcelo F; Torroba A; Ortiz S; Domingo S; Simon C; Mas A
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216305
[TBL] [Abstract][Full Text] [Related]
10. Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization.
Packenham JP; du Manoir S; Schrock E; Risinger JI; Dixon D; Denz DN; Evans JA; Berchuck A; Barrett JC; Devereux TR; Ried T
Mol Carcinog; 1997 Aug; 19(4):273-9. PubMed ID: 9290705
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors.
Chen L; Yang B
Int J Gynecol Pathol; 2008 Jul; 27(3):326-32. PubMed ID: 18580309
[TBL] [Abstract][Full Text] [Related]
12. Chromosome aberrations in uterine smooth muscle tumors: potential diagnostic relevance of cytogenetic instability.
Fletcher JA; Morton CC; Pavelka K; Lage JM
Cancer Res; 1990 Jul; 50(13):4092-7. PubMed ID: 2354458
[TBL] [Abstract][Full Text] [Related]
13. Molecular prognostication of uterine smooth muscle neoplasms: From CGH array to CINSARC signature and beyond.
Croce S; Chibon F
Genes Chromosomes Cancer; 2021 Mar; 60(3):129-137. PubMed ID: 33099852
[TBL] [Abstract][Full Text] [Related]
14. Liquid Biopsy as a Tool for Differentiation of Leiomyomas and Sarcomas of Corpus Uteri.
Dvorská D; Škovierová H; Braný D; Halašová E; Danková Z
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387281
[TBL] [Abstract][Full Text] [Related]
15. [Benign metastatic leiomyoma of the corpus uteri].
Andreeva IuIu; Danilova NV; Shikeeva AA; Kekeeva TV; Zavalishina LE; Frank GA
Arkh Patol; 2012; 74(6):39-43. PubMed ID: 23383444
[TBL] [Abstract][Full Text] [Related]
16. TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma.
Baiocchi G; Poliseli FL; De Brot L; Mantoan H; Schiavon BN; Faloppa CC; Vassallo J; Soares FA; Cunha IW
J Clin Pathol; 2016 Oct; 69(10):884-9. PubMed ID: 26994023
[TBL] [Abstract][Full Text] [Related]
17. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS).
Mayerhofer K; Lozanov P; Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K
Acta Obstet Gynecol Scand; 2004 Nov; 83(11):1085-8. PubMed ID: 15488127
[TBL] [Abstract][Full Text] [Related]
18. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P
Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321
[TBL] [Abstract][Full Text] [Related]
19. MVP immunohistochemistry is a useful adjunct in distinguishing leiomyosarcoma from leiomyoma and leiomyoma with bizarre nuclei.
Lintel NJ; Luebker SA; Lele SM; Koepsell SA
Hum Pathol; 2018 Mar; 73():122-127. PubMed ID: 29307622
[TBL] [Abstract][Full Text] [Related]
20. Molecular analyses of 6 different types of uterine smooth muscle tumors: Emphasis in atypical leiomyoma.
Zhang Q; Ubago J; Li L; Guo H; Liu Y; Qiang W; Kim JJ; Kong B; Wei JJ
Cancer; 2014 Oct; 120(20):3165-77. PubMed ID: 24986214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
